gabapentin · Viatris · NDA 020235, 020882, 021129
Neurontin
Earliest generic entry, as listed · earliest of 6 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 020235-0016 Mar 2026
Products covered · 6
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020235 · 001 · RLD | capsule, oral | 100MG | open |
| 020235 · 002 · RLD | capsule, oral | 300MG | open |
| 020235 · 003 · RLD | capsule, oral | 400MG | open |
| 020882 · 001 · RLD | tablet, oral | 600MG | open |
| 020882 · 002 · RLD | tablet, oral | 800MG | open |
| 021129 · 001 · RLD | solution, oral | 250MG/5ML | open |